United Therapeutics (UTHR) Stock Rating Upgraded by ValuEngine

United Therapeutics (NASDAQ:UTHR) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday.

A number of other analysts have also issued reports on UTHR. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. HC Wainwright reissued a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a research note on Thursday, October 26th. Cowen reaffirmed a “hold” rating and issued a $129.00 price objective on shares of United Therapeutics in a research note on Friday, October 27th. Zacks Investment Research lowered United Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Finally, Oppenheimer reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $138.00.

Shares of United Therapeutics (UTHR) opened at $151.28 on Tuesday. United Therapeutics has a 52 week low of $112.01 and a 52 week high of $169.89. The stock has a market capitalization of $6,480.00, a PE ratio of 13.34 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same period last year, the company earned $4.23 EPS. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. research analysts anticipate that United Therapeutics will post 12.45 EPS for the current year.

In related news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $122.00, for a total transaction of $70,760.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $128.95, for a total value of $160,026.95. The disclosure for this sale can be found here. Insiders sold a total of 18,872 shares of company stock worth $2,302,672 over the last ninety days. Corporate insiders own 7.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. HPM Partners LLC lifted its position in United Therapeutics by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 15 shares in the last quarter. First Allied Advisory Services Inc. increased its holdings in United Therapeutics by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after purchasing an additional 19 shares during the last quarter. Synovus Financial Corp increased its holdings in United Therapeutics by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after purchasing an additional 69 shares during the last quarter. Fort L.P. increased its holdings in United Therapeutics by 5.2% during the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after purchasing an additional 99 shares during the last quarter. Finally, Meiji Yasuda Life Insurance Co increased its holdings in United Therapeutics by 3.8% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 2,760 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 100 shares during the last quarter. 99.99% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/28/united-therapeutics-uthr-stock-rating-upgraded-by-valuengine.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit